Gram Negative Bacterial Infections clinical trials

Explore recruiting gram negative bacterial infections clinical trials.

Recruiting gram negative bacterial infections studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gram Negative Bacterial Infections trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C3601008 - A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION

Hungary, Spain, Greece, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Optimising TREATment for severe Gram-Negative Bacterial infections.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A multicenter, single-arm, open-label study to assess the pharmacokinetics, safety, and tolerability of cefiderocol in hospitalized pediatric patients from birth to < 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections

Spain, Greece, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

C3601010: A Phase 2A, 2-Part, Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam ± Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment

Slovakia, Greece, Bulgaria, Italy, Hungary, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Gram Negative Bacterial Infections trials by city

Gram Negative Bacterial Infections in Toronto Gram Negative Bacterial Infections in Vancouver Gram Negative Bacterial Infections in Montreal Gram Negative Bacterial Infections in Calgary Gram Negative Bacterial Infections in Edmonton Gram Negative Bacterial Infections in Ottawa Gram Negative Bacterial Infections in Winnipeg Gram Negative Bacterial Infections in Quebec City Gram Negative Bacterial Infections in Hamilton Gram Negative Bacterial Infections in Kitchener Gram Negative Bacterial Infections in London Gram Negative Bacterial Infections in Halifax Gram Negative Bacterial Infections in New York Gram Negative Bacterial Infections in Los Angeles Gram Negative Bacterial Infections in Chicago Gram Negative Bacterial Infections in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease